Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Deep Dive: Upper Digestive Cancers - Biliary Cancer: From Molecule To Medicine

ESMO-Deep-Dive-Upper-Digestive-Cancers-1000x250-Biliary
Live on
06 Jul 2022 at 18:30 CEST

It is with great pleasure that we invite you to participate in the ESMO Deep Dive Webinar on biliary tract cancers, elaborating the facts from molecule to medicine.

This webinar is developed with the aim to understand the pathogenesis of biliary tract cancers and how underlying liver disease contributes to the development of these cancers and may inform treatment, as well as to describe mutations and other genetic alterations that inform the current use of both targeted and immune-based therapies in biliary tract cancers, and to learn about emerging biomarkers that hold promise for novel drug developments in the biliary tract cancers.

We will begin with a lecture on implications of aetiology, underlining liver disease and chronic inflammatory disorders in biliary tract cancers. This will follow with elaboration of implications of molecular subgroups for precision cancer medicine. Finally, we will provide an overview of implications of molecular subgroups for immune-based therapy. The lectures will be followed by a live discussion with the speakers’ panel.

This programme is designed to provide an overview of the latest understanding of molecular biology and the impact of targeting different pathways in the management of patients with biliary tract cancers, offer expert opinion exchange and provide some important considerations in this field. We strongly encourage and invite you to register and join us all in this new ESMO activity.

Prof. Andrew Ko
University of California San Francisco (UCSF), San Francisco, United States

AND

Dr. Angela Lamarca
Consultant in Medical Oncology, Fundación Jiménez Díaz, Madrid, Spain

Speakers

Programme

Time

Title

Speaker

5 min

Welcome and Introduction

Andrew Ko, Angela Lamarca

25 min

Implications of aetiology/background liver disease and chronic inflammatory disorders in biliary tract cancers

Marina Baretti

25 min

Implications of molecular subgroups for precision medicine

Rachna Shroff

25 min

Implications of molecular subgroups for immunotherapy

Arndt Vogel

15 min

LIVE Q&A

All

A certificate of attendance and 2 ESMO-MORA category 1 points will be awarded for live attendance to these webinars.

Learning objectives:

  • To understand the pathogenesis of biliary cancers and how underlying liver disease contributes to the development of such cancers and may inform treatment
  • To describe mutations and other genetic alterations that inform the current use of both targeted and immune-based therapies in biliary cancers
  • To learn about emerging biomarkers under investigation that hold promise for novel drug development in this disease

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.